Last edition
News about "Incyte"
Incyte to Acquire Vega Therapeutics, Expanding Hematology Portfolio
Incyte has agreed to acquire Vega Therapeutics, expanding its hematology portfolio into bleeding disorders with the addition of VGA039, a phase 3 investigational monoclonal antibody for von Willebrand disease. The deal includes USD 1.25 billion upfront and up to USD 750 million in additional payments upon achievement of sales milestones.
Incyte | 09/06/2026 | By News Bureau
Incyte and Genesis Molecular AI have expanded their strategic collaboration to deploy advanced molecular AI technologies and proprietary research data, aiming to accelerate drug discovery and develop next-generation therapies through AI-powered molecular design.
Incyte | 22/05/2026 | By News Bureau | 247
Incyte Acquires Escient Pharmaceuticals to Expand its Portfolio
Incyte has signed a definitive agreement with Escient Pharmaceuticals under which Incyte has agreed to acquire Escient, including EP262, a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) and EP547, a first-in-class oral MRGPRX4 antagonist.
Incyte | 24/04/2024 | By Aishwarya | 897
US FDA approval for Incyte's Olumiant
Eli Lilly and Company and Incyte announced the US Food and Drug Administration (FDA) has approved Olumiant (baricitinib) for the treatment of Covid-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days.
Incyte | 12/05/2022 | By Sudeep Soparkar | 913
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy